TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05350215: Atomoxetine and DAW2022 on OSA Severity

Sponsor: Brigham and Women's Hospital · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$4,317,660

Rescue Site Savings

+$2,850,220

Unlock Full NCT05350215 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05350215 Rescue Dossier →